Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
IQVIA Holdings Inc. (IQV) – Form 144 filing discloses a proposed insider sale of common stock under Rule 144.
- Securities offered: 5,800 common shares
- Estimated market value: $1,102,262.16 (≈ $190 per share)
- Broker: Morgan Stanley Smith Barney LLC, New York
- Planned sale date: 23 Jul 2025 on the NYSE
- Total shares outstanding: 170 million; proposed sale equals <0.01% of float
- Source of shares: Stock Appreciation Rights acquired on 23 Jul 2025; consideration paid in cash
The filer states no material non-public adverse information is known. No other sales were made in the past three months. Given the small size relative to IQVIA’s float and the absence of accompanying operational data, the notice is unlikely to affect valuation or liquidity materially.